Medication Monitor



Generic Name (Trade Name—Company)
Notes
November 15, 2012

Amatuximab

(No trade name—Morphotek)
Investigational cancer drug granted orphan status

Uses:

Treatment of malignant pleural mesothelioma

Morphotek announced that FDA has granted orphan drug designation to its investigational cancer drug amatuximab (MORAb-009) for the treatment of malignant pleural mesothelioma. Amatuximab is an investigational chimeric immunoglobulin G1 antibody that targets mesothelin, a cell surface glycoprotein which is over-expressed in a number of cancers. Morphotek noted that mesothelin is thought to be involved in cell adhesion and that its presence has been associated with a wide range of cancers such as pancreatic ductal adenocarcinoma, mesothelioma, epithelial ovarian cancer, and lung adenocarcinoma.